California Academy of Family Physicians (CAFP)
MAY 14, 2025
However, for individuals who do not qualify for federal Medicaid funding—such as most undocumented immigrants—the federal government does not provide matching funds, even when those individuals meet income eligibility requirements. The policy would be effective January 1, 2026.
FDA Law Blog
SEPTEMBER 16, 2024
Regarding CDER’s ETP, the current ETP guidance document, originally published in 2017, will be updated by the end of 2026, and will include details on communicating the type of products and stages of development for which a requestor can approach the ETP. Implementation of the Advanced Manufacturing Technology Designation Program.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA Law Blog
SEPTEMBER 20, 2021
Below we provide an overview of some of the goals letter’s most notable contents such as new initiatives as well as some large-scale enhancements to programs that have already been in the works. Pandemic influences aside, the FY 2023-2027 goals letter contained many notable new initiatives, announcements, and commitments.
Alabama Academy of Family Physicians
FEBRUARY 19, 2025
What Happened: Passed out of the House of Representatives HB 46 – Rural Physicians Tax Credit What’s in the Bill: HB 46 terminates the existing Rural Physician Tax Credit program in Alabama, which provided tax credits to physicians practicing in rural areas, effective December 31, 2025.
FDA Law Blog
NOVEMBER 16, 2021
The Act now extends that delay until January 1, 2026. Medicare Part B reimburses providers for quantities of drugs packaged in single-use containers that are left over after administration and discarded. The new refund requirement applies to drugs that are (1) separately paid under Medicare Part B; (2) single source drugs (i.e.,
FDA Law Blog
AUGUST 14, 2022
The number will begin in 2026 with 10 drug covered under Medicare Part D and will increase annually to 20 Part B and 20 Part D drugs by 2029 and thereafter, with the selected drugs accumulating from year to year. Manufacturers receive no benefits in exchange for the inflation rebates.
FDA Law Blog
SEPTEMBER 14, 2021
A manufacturer that failed to provide access to the MFP would be subject to a civil monetary penalty of ten times the excessive price charged. The AIM price is the volume-weighted average price of the drug in Australia, Canada, France, Germany, Japan, and the U.K. PART 2: INFLATION REBATES UNDER MEDICARE PARTS B AND D.
Expert insights. Personalized for you.
204 
Let's personalize your content